

Speaker Biographies

John L. Berk, M.D.

Director, Clinical Trials for Familial Amyloidosis and Director, Localized Amyloid Clinic, Boston University Amyloidosis Center

As assistant director of Boston University's Amyloidosis Center, Dr. Berk has expertise in pulmonary, localized, and familial amyloidoses with focus on the transthyretin-related diseases. Dr. Berk earned his medical degree at Case Western Reserve University School of Medicine, completing his internship and residency at Case Western's University Hospitals. In addition, he conducted his pulmonary fellowship at Boston University School of Medicine and a Howard Hughes Medical Institute research fellowship. Dr. Berk serves on the editorial board of *Amyloid: the journal of protein folding disorders* and has authored or co-authored numerous publications related to amyloidosis. He designed and lead the international, multi-centered Diflunisal Trial, and has acted as a principal investigator for a number of amyloidosis clinical research studies including Alnylam's APOLLO study evaluating the efficacy and safety of patisiran in hereditary transthyretin (TTR)-mediated amyloidosis with polyneuropathy (hATTR-PN).

Christina Lindsey

Patient living with ATTR amyloidosis

Christina Lindsey lives in Virginia with her husband, an active duty Marine, and their four children. Christina, who has a family history of amyloidosis dating back several generations, was positively diagnosed in 2003 and is increasingly experiencing symptoms of disease progression including extreme fatigue, neuropathic pain, severe GI distress and retinal damage. When her husband is deployed, Christina is singularly responsible for caring for her children, including homeschooling them, driving them to appointments and maintaining a healthy and happy home environment.

Eric Green

Vice President, General Manager, TTR Program

Mr. Green joined Alnylam in 2015, having most recently worked at Synageva BioPharma, where he was Vice President of Program and Alliance Management. In that role he was responsible for the oversight, management, and leadership of the company's lead compound being developed as an enzyme replacement therapy for an ultra-orphan genetic disease. Prior to Synageva, he worked as Senior Director, Product Development and Program Management at Infinity Pharmaceuticals, and he spent over eight years at Genzyme Corporation, where he served in roles of increasing responsibility in program and brand management for multiple commercial oncology products. Eric received his Bachelor of Science in Chemical Engineering from the University of Michigan, a Masters in Chemical Engineering from the Massachusetts Institute of Technology (MIT), and an MBA from the MIT Sloan School of Management.

Jared Gollob, M.D.

Vice President, Clinical Research

Dr. Gollob joined Alnylam in 2007 and has worked across multiple programs within the clinical development organization, including serving in a program leadership role for the company's ALN-TTR programs. Prior to Alnylam, he was an Associate Professor of Medicine and Director of the Biologic Therapy Program at Duke University Medical Center, with a secondary appointment as Associate Professor of Immunology. He was also concurrently Head of Hematology/Oncology at the Duke VA Medical Center. Jared received his A.B. and M.D. from Columbia University, and then completed his clinical training at Massachusetts General Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute. Jared is a board certified Medical Oncologist with interests in tumor biology and development of new treatments for renal cell carcinoma and melanoma. Previously, he has advised Chiron, Schering-Plough, Bayer, and Novartis on their oncology programs.